Investors should be aware that biotech companies, especially in the stem-cell space, tend to move with the news flow, ... If there's bad news, like if Bush vetoes this bill as he promised he will, the prices could go back to more reasonable valuations.

275

It's very beneficial to the space. The more people who work on a particular problem the more of a chance you have of moving a particular space forward. It opens up a lot options now in the embryonic stem cell space.

253

You might see -- for lack of a better word -- money being thrown around for different therapies. There could be a number of winners.

222

A lot of biotechnology companies are in the research and development stages, ... From a fundamental point of view, investors need to look at valuation and calculate the potential for success with any therapy.

176

It gives them more leverage. If your cost of goods is lower, you have more leverage to negotiate prices that might be able to beat out competing technologies.

105